Pelagra: Evidence‑Based Diagnosis and Management

Clinical Presentation

• The disease is identified clinically by the classic “3 D” syndrome—dermatitis, diarrhea, and dementia—and, if untreated, can progress to death (the “4 D”). [1][2]

• Bilateral, symmetric, photosensitive dermatitis occurs on sun‑exposed skin (dorsum of the hands, face, neck, and chest). [1][2]

Etiology and High‑Risk Populations

• Primary cause: a diet heavily dependent on corn or overall protein‑energy malnutrition, commonly linked to poverty, neglect, famine, or eating‑disorder‑related starvation. [1][2]

• Secondary cause: chronic alcohol abuse. [1][2]

• Secondary cause: generalized malabsorption conditions such as prolonged diarrheal illness. [1][2]

• Secondary cause: carcinoid tumors and other metabolic disorders. [1][2]

• Secondary cause: specific drugs—including long‑term chemotherapy agents, 5‑fluorouracil, isoniazid, pyrazinamide, ethionamide, 6‑mercaptopurine, hydantoins, phenobarbital, and chloramphenicol. 1

• High‑risk groups: elderly individuals and pregnant women, who have increased niacin requirements. [1][2]

• High‑risk groups: oncology patients receiving radiotherapy or DNA‑damaging chemotherapeutic agents. [1][2]

• High‑risk groups: persons whose diet consists mainly of refined, non‑fortified grains. [1][2]

Laboratory Diagnosis

• Blood or tissue nicotinamide adenine dinucleotide (NAD) levels can be measured when the clinical triad is present, providing a direct biochemical assessment of niacin status. [1][3]

• A pragmatic approach is to collect a blood sample and observe clinical improvement after niacin supplementation, useful when NAD testing is not readily available. [1][3]

• Urinary nicotinamide metabolites—nicotinamide mononucleotide (NMN) and 2‑pyridone (2‑Pyr)—are reliable markers of systemic niacin adequacy. [2][3]

Treatment

• Physiological supplementation with nicotinic acid 15–20 mg per day or nicotinamide 300 mg per day effectively reverses traditional pelagra. [1][2]

• Oral or enteral administration is preferred whenever the gastrointestinal tract is functional. [1][4]

• Parenteral niacin delivery may be employed in cases of severe malabsorption or short‑bowel syndrome. 1

Diagnostic and Management Guidelines for Pellagra

Diagnosis

• The diagnosis of pellagra is based primarily on the classic clinical triad of dermatitis, diarrhea, and dementia; although whole‑blood NAD levels can be measured, they are unreliable, and the most practical approach is to obtain a blood sample and assess clinical improvement after oral niacin supplementation. 5

Laboratory Assessment

Biochemical Markers

• Urinary niacin metabolites—1‑methyl‑2‑pyridone‑5‑carboxamide (2‑PYR) and 1‑methyl‑nicotinamide (1‑MN)—are the most sensitive and specific biochemical markers for detecting niacin deficiency. 5

• Whole‑blood concentrations of NAD and NADP are not significantly reduced in patients with clinical pellagra, which can lead to an underestimation of the deficiency. 5

• The NAD : NADP ratio, although proposed as an indicator of niacin status, has been shown to be unreliable in the setting of clinical pellagra. 6

Pragmatic Testing Strategy

• When NAD testing is not readily available, guidelines recommend preserving a blood sample and observing the patient’s symptom response after oral niacin supplementation as a pragmatic diagnostic alternative. [5][7]

Risk Populations

• Populations at increased risk for pellagra include: chronic alcohol use disorder, gastrointestinal malabsorption syndromes, anorexia nervosa, elderly individuals and pregnant women (due to higher niacin requirements), oncology patients receiving radiotherapy or chemotherapy, and patients with carcinoid tumors or other metabolic disorders. [5][6]

• Diets that rely predominantly on non‑fortified refined cereals markedly elevate the risk of developing pellagra. 8

Management

• Therapeutic regimens of oral nicotinic acid 15–20 mg per day or nicotinamide 300 mg per day effectively reverse the manifestations of traditional pellagra. 5

Prognosis

• If pellagra is not promptly recognized and treated, it can lead to death. 8

Guidelines for Management of Niacin (Vitamin B3) Deficiency

Indications for Initiating Treatment

• Oral nicotinic acid 15–20 mg/day or nicotinamide 300 mg/day should be started in patients with confirmed or suspected niacin deficiency to reverse pellagra and restore niacin status【9】【10】.
• Higher daily doses may be required when a patient has a high‑risk history (e.g., chronic alcohol use, malabsorption) or presents with signs such as dermatitis, diarrhea, or neurocognitive changes【9】.
• Elderly individuals and pregnant women have increased niacin requirements and should be treated when deficiency is suspected【9】【10】.
• Patients undergoing radiotherapy or DNA‑damaging chemotherapy for cancer are at risk of deficiency and merit supplementation【9】【10】.
• Individuals with carcinoid or serotonin‑producing neuroendocrine tumors are prone to deficiency and should receive niacin therapy【10】.
• Persons whose diet consists mainly of non‑fortified refined grains are at risk and warrant treatment【9】【10】.
• Patients with chronic malabsorption syndromes or prolonged diarrheal illness should be supplemented to prevent deficiency【10】.

Recommended Dosage and Route

• Standard oral/enteral regimen – nicotinic acid 15–20 mg/day or nicotinamide 300 mg/day administered orally when the gastrointestinal tract is functional【9】【10】.
• The oral/enteral route is preferred whenever possible because it is effective and simple to administer【9】【10】.
• Parenteral supplementation – indicated for severe malabsorption or short‑bowel syndrome; parenteral nutrition formulas must contain at least 40 mg of niacin per day【10】【9】.
• Maintenance for enteral feeding – provide 18–40 mg of niacin per 1500 kcal of enteral formula【9】.
• Maintenance for parenteral feeding – ensure a minimum of 40 mg niacin per day in the parenteral mixture【9】.

Choice Between Nicotinic Acid and Nicotinamide

• Nicotinamide is preferred for most patients because it has a lower adverse‑effect profile, notably the absence of flushing【11】【12】.
• Nicotinamide can be given up to approximately 900 mg/day in adults without flushing, whereas nicotinic acid commonly causes flushing at doses as low as 30 mg and should not exceed 10 mg/day for free acid formulations【11】【9】【12】.
• Both nicotinic acid and nicotinamide are equally effective at physiological doses for treating pellagra【9】【10】.

Monitoring Treatment Response

• When NAD testing is unavailable, clinicians should obtain a baseline blood sample and assess clinical improvement after niacin supplementation as a pragmatic monitoring strategy【9】【10】.
• This pragmatic approach is often more practical than awaiting laboratory confirmation【9】.
• If laboratory resources exist, blood or tissue NAD concentrations can be measured in symptomatic patients【9】.
• Urinary niacin metabolites (N‑methyl‑nicotinamide and N‑methyl‑2‑pyridone‑carboxamide) serve as reliable biochemical markers of niacin status【11】【12】.

Safety and Toxicity Considerations

• Hepatotoxicity may occur with niacin doses around 3 g/day, ranging from mild enzyme elevation to acute liver failure【9】【10】.
• Flushing is a dose‑dependent effect of nicotinic acid (as low as 30 mg) and does not occur with nicotinamide【11】【9】【12】.
• Adverse effects are more frequent at higher doses and in patients with renal impairment; routine monitoring is generally unnecessary for nicotinamide doses below 1500 mg/day【11】.

Nutritional Cofactors for Endogenous Niacin Synthesis

• Enteral formulas should contain at least 1.2 mg/day of riboflavin (vitamin B2), which is required for the conversion of tryptophan to niacin【11】【13】.
• The tryptophan‑to‑niacin pathway also depends on thiamine (vitamin B1) and pyridoxine (vitamin B6) as essential cofactors【11】【13】.